Roche: Tecentriq combination reduces lung cancer risk
(CercleFinance.com) - Roche's Tecentriq plus chemotherapy prolonged the time people with advanced lung cancer lived without their disease worsening, a clinical trial showed.
The Swiss drugmaker today announced that a Phase III study met its co-primary endpoint of progression-free survival and demonstrated that the combination reduced the risk of disease worsening or death compared to chemotherapy alone in people with advanced non-squamous non-small cell lung cancer (NSCLC).
The randomised study enrolled 568 people.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Swiss drugmaker today announced that a Phase III study met its co-primary endpoint of progression-free survival and demonstrated that the combination reduced the risk of disease worsening or death compared to chemotherapy alone in people with advanced non-squamous non-small cell lung cancer (NSCLC).
The randomised study enrolled 568 people.
Copyright (c) 2018 CercleFinance.com. All rights reserved.